Genenta's CEO Invests Big: What It Means for the Company

CEO's Investment

Genenta Science, a company pioneering new cancer treatments, has revealed that its CEO, Pierluigi Paracchi, has been acquiring shares.

• 30,000 ADSs purchased through open-market buys.
• No sales reported, only purchases.

As of December 19, 2025, Paracchi owns:

• 2,326,129 ADSs and ordinary shares
• ~10% of all shares in circulation.

This move signals confidence—CEOs often invest personally when they believe in their company's future.

Genenta's Innovations

Genenta is developing gene therapy treatments for solid tumors.

Temferon™

• Phase 1 trial completed for Glioblastoma Multiforme (brain cancer).
• Results suggest the treatment may:
• Reprogram the tumor environment.
• Boost the immune response.

Ongoing Trials

• Phase 1/2a trial for metastatic Renal Cell Carcinoma.
• Exploring combinations with other therapies to enhance effectiveness.

Risks & Rewards

While promising, clinical-stage companies face uncertainties:

• Treatments are not yet approved.
• Trials can be unpredictable.

However, if successful, Genenta’s innovations could be a game-changer in cancer treatment.